Multiple myeloma derived from a kidney transplant donor who also developed myeloma after kidney donation

Abstract

| INTRODUC TI ONPatients with kidney transplants are associated with an approximately 2-to 3-fold higher risk of cancer compared with the general population. 1 This is mainly explained by the long-term use of immunosuppressive agents to prevent allograft rejection. Most postrenal transplant cancers are considered to originate from the recipient. 2 However, donor-related cancers have been reported in both sporadic case reports and case series since the 1970s. 3-5 Donor-related cancers are extremely rare; based on registry data, the cadaveric donorrelated cancer rate is reportedly 0.04% in all organ transplants. 4Donor-transmitted cancers (cancers present or considered to be present in the donor at the time of transplantation 6 ) have been described in the literature. In a systematic review that analyzed 104 donortransmitted cancers by renal graft, the most common types of transmitted cancer were renal cancer, melanoma, lymphoma, and lung cancer. 5 In addition, there have been several reports about donor-derived cancers (de novo cancers developing in transplanted donor cells). 4,7,8 Herein we report a case of postrenal transplant multiple myeloma diagnosed 7 years after kidney transplantation. Of interest, the myeloma cells originated from the donor, who developed multiple myeloma 1 year after kidney donation.

Successful kidney transplantation in a patient with pre-existing chronic myeloid leukemia treated with imatinib

“…Which other factors may contribute to the increased risk of CML and other hematologic cancers among patients with end‐stage renal disease is not well understood 15 . Basically, hematologic malignancies can be transferred by solid organ transplantation as has recently been reported for donor‐derived B cell acute lymphoblastic leukemia 16 or donor‐derived multiple myeloma 17 after kidney transplantation. However, the possibility of a donor‐derived origin of CML in our patient could be ruled out by DNA typing using a 16‐loci short tandem repeat multiplex system (PowerPlex ® 16 HS System, Promega, Madison, Wisconsin), which revealed an unmixed microsatellite profile with complete match between bone marrow taken at initial diagnosis of CML and different other tissues (colon, prostate) of the same patient.…”